ReiThera Opens New Large-Scale Viral Vector Manufacturing Facility
Leading contract development and manufacturing organization (CDMO) ReiThera has announced that it has received operational authorization from the Italian Medicines Agency (AIFA) to open a new facility for the large-scale production of viral vectors for vaccines and gene therapies.
ReiThera’s Chief of Technology Stefano Colloca sat down with Phacilitate to tell us about ReiThera’s journey and the impact of its new facilities, ahead of its exhibition appearance at Advanced Therapies Week 2023!
Located at ReiThera’s pharmaceutical facility at the Castel Romano Technopole, construction of this specialized production area began back in May 2020 – following ReiThera’s investment of 15 million euros.
This 1,500 sq.m. world-class facility will provide space to meet the growing demand for manufacturing in this area, and provide ReiThera’s biotechnological clients, including both small and start-up companies as well as multinational pharma groups, access to advanced GMP technologies and maximum-scale-up flexibility.
The facility will feature the latest generation bioreactors with scaled volume capacities of 200, 1,000, and 2,000. This will accommodate the GMP production of therapeutics based on Adenovirus, Adeno-associated Virus, and Lentivirus, from 50 liters up to 3,000 liters.
How are you enjoying this news article? Let us know your thoughts, here >>
ReiThera is dedicated to the technical development, GMP manufacturing, and clinical translation of gene-based therapies including vaccines and medicinal products.
Scientists at ReiThera have developed an innovative platform based on simian adenoviral vectors that have multiple therapeutic applications. They have already successfully developed genetic vaccines against many major infectious diseases including HIV, hepatitis C, and malaria.
“Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive experience in the engineering and bioprocessing of viral vectors, will be able to support companies engaged in the development of products in the field of vaccines and advanced therapies, from the fine-tuning of small-scale production processes to production on a commercial scale,” said Stefano Colloca, ReiThera CTO and Co-founder.
Developers at ReiThera are currently working on scalable platforms for other viral vectors including AAV, LV, MVA and HSV.
Source: ReiThera Press Release
You can catch the ReiThera team at Advanced Therapies Week 2023, Booth 629, Exhibit Show Floor!
Join us at Advanced Therapies Week >>
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to firstname.lastname@example.org.